Black Diamond Therapeutics (BDTX) Common Equity (2018 - 2026)

Black Diamond Therapeutics (BDTX) has reported Common Equity for 9 consecutive years, with $96.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 27.54% year-over-year to $96.1 million; the trailing twelve-month figure through Jun 2026 stood at $96.1 million (down 27.54% YoY), and the FY2025 full-year result was $112.2 million, up 34.73% from the prior year.
• Common Equity declined to $96.1 million in Q2 2026 per BDTX's latest filing, from $104.3 million in the prior quarter.
• Across five years, Common Equity topped out at $172.6 million in Q1 2022 and bottomed at $82.2 million in Q2 2023.
• Historically, Common Equity has averaged $117.4 million across 5 years, with a median of $114.0 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Common Equity sank 46.05% in 2023, then jumped 35.67% in 2025.
• Over 5 years, Common Equity stood at $115.7 million in 2022, then grew by 0.9% to $116.7 million in 2023, then decreased by 28.66% to $83.3 million in 2024, then jumped by 34.73% to $112.2 million in 2025, then dropped by 14.37% to $96.1 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $96.1 million, $104.3 million, and $112.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.